London SW1H 0DB
44 20 7400 3347
Full-time employees: 863
|Mr. Matthew Gline||CEO & Director||1.45M||N/A||1984|
|Dr. Eric Venker M.D., Pharm.D.||Pres & COO||981.38k||N/A||1987|
|Dr. Mayukh Sukhatme M.D.||Pres & Chief Investment Officer||910.19k||N/A||1976|
|Mr. Richard Pulik||Chief Financial Officer||N/A||N/A||1980|
|Ms. Rakhi Kumar||Chief Accounting Officer||N/A||N/A||1980|
|Dr. Huafeng Xu Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Josh Chen||Gen. Counsel||N/A||N/A||N/A|
|Ms. Kelly Graff||Head of People||N/A||N/A||N/A|
|Ms. Marianne L. Romeo||Head of Global Transactions & Risk Management||N/A||N/A||1968|
|Mr. Alex Gasner||Exec. VP of Roivant Health||N/A||N/A||N/A|
Roivant Sciences Ltd. focuses on discovery, development, and commercialization of medicines. It develops transformative medicines by building technologies and developing talent in creative ways, leveraging its platform to launch Vants nimble and focuses biopharmaceutical and health technology companies. The company was founded in 2014 and is based in London, the United Kingdom.
Roivant Sciences Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.